USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis

Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials

Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData

Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024

Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules

Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.

Boehringer Ingelheim’s treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program

Good microbiome and probiotics key to good health

The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram

Intravacc publishes a GMP process for a semi-synthetic Shigella glycoconjugate vaccine

Data published in the prestigious journal ACS Central Science of the American Chemical Society

Wadia Hospital, Mumbai introduces tests for cystic fibrosis

This test is inexpensive and results are available immediately as compared to the genetic test

Lupin launches authorized generic version of Alinia

Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.